Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q16773

UPID:
KAT1_HUMAN

ALTERNATIVE NAMES:
Cysteine-S-conjugate beta-lyase; Glutamine transaminase K; Glutamine--phenylpyruvate transaminase; Kynurenine aminotransferase 1; Kynurenine aminotransferase I; Kynurenine--oxoglutarate transaminase I

ALTERNATIVE UPACC:
Q16773; Q5T275; Q8N191

BACKGROUND:
Kynurenine--oxoglutarate transaminase 1, identified by alternative names such as Glutamine transaminase K and Kynurenine aminotransferase I, is pivotal in the tryptophan degradation pathway. It facilitates the formation of kynurenic acid from L-kynurenine, a key step influencing neurotransmission through its antagonistic effects on excitatory amino acid receptors. The enzyme's ability to process cysteine conjugates and eliminate S-conjugates and Se-conjugates further underscores its critical role in maintaining cellular health by neutralizing potentially harmful substances.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Kynurenine--oxoglutarate transaminase 1 offers promising avenues for the development of treatments targeting diseases associated with neurotransmitter imbalances and toxic metabolite accumulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.